Gilead to pay $120 million for kinase biology company

Gilead Sciences Inc has agreed to pay up to $120 million to acquire CGI Pharmaceuticals Inc, a privately-held US company with a library of small molecule kinase inhibitors. CGI’s lead preclinical compound may have application in RA.